VRTX
Research Snapshot
Static fundamentals, valuation context, and investor signals for VERTEX PHARMACEUTICALS INC / MA (VRTX).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
21.2%
ROIC, 26.6% FCF margin
Growth
14.1%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 2.9x current ratio
Superinvestors
2
Top: Tweedy Browne Co. (1.4%)
Strengths to research
- Revenue compounded at 14.1% over five years.
- Return on equity is strong at 21.2%.
- Free cash flow margin is healthy at 26.6%.
- Debt/equity looks manageable at 0.0x.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for VRTX.
Grade D
38
/ 100
Financial Charts
No financial data available for VRTX (annual).
2 superinvestors own VRTX
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Tweedy Browne Co. Tweedy Browne Value Fund | 40,387 | $18M | 1.43% | 0.0% |
| Torray Funds Torray Funds | 15,386 | $7M | 1.08% | 0.0% |